Investment & Fund Management

The European Investment Fund (EIF) supported Ysios Capital, a prominent biotechnology venture capital firm in Spain, in the successful closing of its second fund, Ysios BioFund II Innvierte FCR, which raised €126.4 million, surpassing its initial target of €100 million. This fund focuses on investing in early-stage and development-phase biotech, medtech, and diagnostic companies across Europe, with a particular emphasis on Spain. The fund aims to finance up to 15 companies that offer disruptive products and technologies addressing unmet medical needs.

Ysios BioFund II Innvierte has attracted a diverse and strengthened investor base, including both returning and new institutional investors such as the CDTI (Spanish Ministry of Economy) through its Innvierte program, the EIF, and the European Commission via InnovFin SME Venture Capital. The fund has already made significant investments in five companies, including Sanifit and Minoryx Therapeutics, marking the largest transactions in the history of the biotech sector in Spain and Barcelona, respectively.

The success of this fund is attributed to the dedicated efforts of an international team at Ysios Capital, which has been instrumental in drawing specialized international funds and corporate venture funds to Spain, thereby representing a pivotal moment for the country's biotech sector. In 2015 alone, portfolio companies of Ysios Capital in Spain secured €100 million in capital, showcasing the fund's impact on enhancing financing options for SMEs in the biotechnology field.